Literature DB >> 18451212

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.

Mark B Meads1, Lori A Hazlehurst, William S Dalton.   

Abstract

The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of hematopoietic cells. These cells are supported by fibroblast-like bone marrow stromal cells, osteoblasts, and osteoclasts which secrete soluble factors and extracellular matrix proteins that mediate these functions. This rich environment serves as a safe haven not only for normal and malignant hematopoietic cells, but also for epithelial tumor cells that metastasize to bone, offering protection from chemotherapeutic agents by common mechanisms. Soluble factors produced in the bone marrow, such as stromal cell-derived factor-1 and interleukin-6, mediate homing, survival, and proliferation of tumor cells, and integrin-mediated adhesion sequesters tumor cells to this protective niche. Environment-mediated drug resistance includes a combination of soluble factors and adhesion, and can be subdivided into soluble factor-mediated drug resistance and cell adhesion-mediated drug resistance. Because it is induced immediately by the microenvironment and is independent of epigenetic or genetic changes caused by the selective pressure of drug exposure, environment-mediated drug resistance is a form of de novo drug resistance. In this form of drug resistance, tumor cells are transiently and reversibly protected from apoptosis induced by both chemotherapy and physiologic mediators of cell death. This protection allows tumor cells to survive the insult of chemotherapy, leading to minimal residual disease, and thereby increases the probability for the development of acquired drug resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451212     DOI: 10.1158/1078-0432.CCR-07-2223

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  241 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

2.  Respiratory syncytial virus infection in human bone marrow stromal cells.

Authors:  Fariba Rezaee; Laura F Gibson; Debbie Piktel; Sreekumar Othumpangat; Giovanni Piedimonte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-22       Impact factor: 6.914

3.  Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

Authors:  Januario E Castro; Johanna Melo-Cardenas; Mauricio Urquiza; Juan S Barajas-Gamboa; Ramin S Pakbaz; Thomas J Kipps
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

4.  Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.

Authors:  Ariosto S Silva; Robert A Gatenby
Journal:  Mol Pharm       Date:  2011-10-12       Impact factor: 4.939

Review 5.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

6.  CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model.

Authors:  Urszula M Domanska; Jennifer C Boer; Hetty Timmer-Bosscha; Marcel A T M van Vugt; Hilde D Hoving; Nathalie M Kliphuis; Stefano Rosati; Henk G van der Poel; Igle Jan de Jong; Elisabeth G E de Vries; Annemiek M E Walenkamp
Journal:  Clin Exp Metastasis       Date:  2014-08-26       Impact factor: 5.150

7.  Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.

Authors:  Vincent Crenn; Kevin Biteau; Jérôme Amiaud; Clotilde Dumars; Romain Guiho; Luciano Vidal; Louis-Romée Le Nail; Dominique Heymann; Anne Moreau; François Gouin; Françoise Redini
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

8.  Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Authors:  M B Meads; B Fang; L Mathews; J Gemmer; L Nong; I Rosado-Lopez; T Nguyen; J E Ring; W Matsui; A R MacLeod; J A Pachter; L A Hazlehurst; J M Koomen; K H Shain
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 9.  Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Authors:  Yulia Nefedova; Dmitry Gabrilovich
Journal:  Drug Resist Updat       Date:  2008-10-31       Impact factor: 18.500

10.  IL-6 and MYC collaborate in plasma cell tumor formation in mice.

Authors:  Sebastian Rutsch; Vishala T Neppalli; Dong-Mi Shin; Wendy DuBois; Herbert C Morse; Hartmut Goldschmidt; Siegfried Janz
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.